Literature DB >> 19204007

Mutant huntingtin N-terminal fragments of specific size mediate aggregation and toxicity in neuronal cells.

Tamara Ratovitski1, Marjan Gucek, Haibing Jiang, Ekaterine Chighladze, Elaine Waldron, James D'Ambola, Zhipeng Hou, Yideng Liang, Michelle A Poirier, Ricky R Hirschhorn, Rona Graham, Michael R Hayden, Robert N Cole, Christopher A Ross.   

Abstract

Huntingtin proteolysis is implicated in Huntington disease pathogenesis, yet, the nature of huntingtin toxic fragments remains unclear. Huntingtin undergoes proteolysis by calpains and caspases within an N-terminal region between amino acids 460 and 600. We have focused on proteolytic steps producing shorter N-terminal fragments, which we term cp-1 and cp-2 (distinct from previously described cp-A/cp-B). We used HEK293 cells to express the first 511 residues of huntingtin and further define the cp-1 and cp-2 cleavage sites. Based on epitope mapping with huntingtin-specific antibodies, we found that cp-1 cleavage occurs between residues 81 and 129 of huntingtin. Affinity and size exclusion chromatography were used to further purify huntingtin cleavage products and enrich for the cp-1/cp-2 fragments. Using mass spectrometry, we found that the cp-2 fragment is generated by cleavage of huntingtin at position Arg(167). This site was confirmed by deletion analysis and specific detection with a custom-generated cp-2 site neo-epitope antibody. Furthermore, alterations of this cleavage site resulted in a decrease in toxicity and an increase in aggregation of huntingtin in neuronal cells. These data suggest that cleavage of huntingtin at residue Arg(167) may mediate mutant huntingtin toxicity in Huntington disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19204007      PMCID: PMC2667772          DOI: 10.1074/jbc.M804813200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  43 in total

1.  Progressive phenotype and nuclear accumulation of an amino-terminal cleavage fragment in a transgenic mouse model with inducible expression of full-length mutant huntingtin.

Authors:  Yuji Tanaka; Shuichi Igarashi; Masayuki Nakamura; Juliette Gafni; Cameron Torcassi; Gabrielle Schilling; Danielle Crippen; Jonathan D Wood; Akira Sawa; Nancy A Jenkins; Neal G Copeland; David R Borchelt; Christopher A Ross; Lisa M Ellerby
Journal:  Neurobiol Dis       Date:  2005-09-16       Impact factor: 5.996

2.  Determination of peptide substrate specificity for mu-calpain by a peptide library-based approach: the importance of primed side interactions.

Authors:  Dominic Cuerrier; Tudor Moldoveanu; Peter L Davies
Journal:  J Biol Chem       Date:  2005-10-10       Impact factor: 5.157

3.  Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin.

Authors:  Rona K Graham; Yu Deng; Elizabeth J Slow; Brendan Haigh; Nagat Bissada; Ge Lu; Jacqueline Pearson; Jacqueline Shehadeh; Lisa Bertram; Zoe Murphy; Simon C Warby; Crystal N Doty; Sophie Roy; Cheryl L Wellington; Blair R Leavitt; Lynn A Raymond; Donald W Nicholson; Michael R Hayden
Journal:  Cell       Date:  2006-06-16       Impact factor: 41.582

Review 4.  Opinion: What is the role of protein aggregation in neurodegeneration?

Authors:  Christopher A Ross; Michelle A Poirier
Journal:  Nat Rev Mol Cell Biol       Date:  2005-11       Impact factor: 94.444

5.  Lysosomal proteases are involved in generation of N-terminal huntingtin fragments.

Authors:  Yun J Kim; Ellen Sapp; Benjamin G Cuiffo; Lindsay Sobin; Jennifer Yoder; Kimberly B Kegel; Zheng-Hong Qin; Peter Detloff; Neil Aronin; Marian DiFiglia
Journal:  Neurobiol Dis       Date:  2006-01-19       Impact factor: 5.996

Review 6.  Lessons from animal models of Huntington's disease.

Authors:  David C Rubinsztein
Journal:  Trends Genet       Date:  2002-04       Impact factor: 11.639

Review 7.  The role of amyloid beta peptide 42 in Alzheimer's disease.

Authors:  Mark A Findeis
Journal:  Pharmacol Ther       Date:  2007-07-17       Impact factor: 12.310

8.  Absence of behavioral abnormalities and neurodegeneration in vivo despite widespread neuronal huntingtin inclusions.

Authors:  Elizabeth J Slow; Rona K Graham; Alexander P Osmand; Rebecca S Devon; Ge Lu; Yu Deng; Jacqui Pearson; Kuljeet Vaid; Nagat Bissada; Ronald Wetzel; Blair R Leavitt; Michael R Hayden
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-02       Impact factor: 11.205

9.  N-terminal proteolysis of full-length mutant huntingtin in an inducible PC12 cell model of Huntington's disease.

Authors:  Tamara Ratovitski; Masayuki Nakamura; James D'Ambola; Ekaterine Chighladze; Yideng Liang; Wenfei Wang; Rona Graham; Michael R Hayden; David R Borchelt; Ricky R Hirschhorn; Christopher A Ross
Journal:  Cell Cycle       Date:  2007-12-01       Impact factor: 4.534

10.  Characterization of huntingtin pathologic fragments in human Huntington disease, transgenic mice, and cell models.

Authors:  Gabriele Schilling; Alexandra Klevytska; Andrew T N Tebbenkamp; Katrin Juenemann; Jillian Cooper; Victoria Gonzales; Hilda Slunt; Michelle Poirer; Christopher A Ross; David R Borchelt
Journal:  J Neuropathol Exp Neurol       Date:  2007-04       Impact factor: 3.685

View more
  67 in total

1.  Transgenic mice expressing caspase-6-derived N-terminal fragments of mutant huntingtin develop neurologic abnormalities with predominant cytoplasmic inclusion pathology composed largely of a smaller proteolytic derivative.

Authors:  Andrew T N Tebbenkamp; Cameron Green; Guilian Xu; Eileen M Denovan-Wright; Aaron C Rising; Susan E Fromholt; Hilda H Brown; Debbie Swing; Ronald J Mandel; Lino Tessarollo; David R Borchelt
Journal:  Hum Mol Genet       Date:  2011-04-22       Impact factor: 6.150

2.  Mass spectrometric identification of novel posttranslational modification sites in Huntingtin.

Authors:  Gaofeng Dong; Eduardo Callegari; Christian J Gloeckner; Marius Ueffing; Hongmin Wang
Journal:  Proteomics       Date:  2012-06       Impact factor: 3.984

3.  Global Proteome and Ubiquitinome Changes in the Soluble and Insoluble Fractions of Q175 Huntington Mice Brains.

Authors:  Karen A Sap; Arzu Tugce Guler; Karel Bezstarosti; Aleksandra E Bury; Katrin Juenemann; Jeroen A A Demmers; Eric A Reits
Journal:  Mol Cell Proteomics       Date:  2019-05-28       Impact factor: 5.911

4.  Aggregation landscapes of Huntingtin exon 1 protein fragments and the critical repeat length for the onset of Huntington's disease.

Authors:  Mingchen Chen; Peter G Wolynes
Journal:  Proc Natl Acad Sci U S A       Date:  2017-04-11       Impact factor: 11.205

5.  Structure and topology of the huntingtin 1-17 membrane anchor by a combined solution and solid-state NMR approach.

Authors:  Matthias Michalek; Evgeniy S Salnikov; Burkhard Bechinger
Journal:  Biophys J       Date:  2013-08-06       Impact factor: 4.033

6.  Identification of a post-translationally myristoylated autophagy-inducing domain released by caspase cleavage of huntingtin.

Authors:  Dale D O Martin; Ryan J Heit; Megan C Yap; Michael W Davidson; Michael R Hayden; Luc G Berthiaume
Journal:  Hum Mol Genet       Date:  2014-01-23       Impact factor: 6.150

Review 7.  New insight into neurodegeneration: the role of proteomics.

Authors:  Ramavati Pal; Guido Alves; Jan Petter Larsen; Simon Geir Møller
Journal:  Mol Neurobiol       Date:  2013-12-10       Impact factor: 5.590

8.  Proteolysis of mutant huntingtin produces an exon 1 fragment that accumulates as an aggregated protein in neuronal nuclei in Huntington disease.

Authors:  Christian Landles; Kirupa Sathasivam; Andreas Weiss; Ben Woodman; Hilary Moffitt; Steve Finkbeiner; Banghua Sun; Juliette Gafni; Lisa M Ellerby; Yvon Trottier; William G Richards; Alex Osmand; Paolo Paganetti; Gillian P Bates
Journal:  J Biol Chem       Date:  2010-01-19       Impact factor: 5.157

9.  Cholesterol Modifies Huntingtin Binding to, Disruption of, and Aggregation on Lipid Membranes.

Authors:  Xiang Gao; Warren A Campbell; Maxmore Chaibva; Pranav Jain; Ashley E Leslie; Shelli L Frey; Justin Legleiter
Journal:  Biochemistry       Date:  2015-12-22       Impact factor: 3.162

Review 10.  The role of amyloidogenic protein oligomerization in neurodegenerative disease.

Authors:  Gregor P Lotz; Justin Legleiter
Journal:  J Mol Med (Berl)       Date:  2013-03-27       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.